NEW YORK (GenomeWeb) – Molecular Stethoscope announced today the completion of an $8.2 million seed financing, which will enable the company to continue developing its liquid biopsy tests for cardiometabolic and neurodegenerative diseases.

Additionally, the company has signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay that can identify subjects at critical stages of disease progression in key cardiometabolic conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.